Antonio Scalfari

3.1k total citations · 3 hit papers
46 papers, 1.9k citations indexed

About

Antonio Scalfari is a scholar working on Pathology and Forensic Medicine, Neurology and Rheumatology. According to data from OpenAlex, Antonio Scalfari has authored 46 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Pathology and Forensic Medicine, 17 papers in Neurology and 14 papers in Rheumatology. Recurrent topics in Antonio Scalfari's work include Multiple Sclerosis Research Studies (35 papers), Peripheral Neuropathies and Disorders (13 papers) and Rheumatoid Arthritis Research and Therapies (9 papers). Antonio Scalfari is often cited by papers focused on Multiple Sclerosis Research Studies (35 papers), Peripheral Neuropathies and Disorders (13 papers) and Rheumatoid Arthritis Research and Therapies (9 papers). Antonio Scalfari collaborates with scholars based in United Kingdom, Italy and Germany. Antonio Scalfari's co-authors include George C. Ebers, Paolo A. Muraro, Martin Däumer, Alexandra Degenhardt, Ain Neuhaus, Anneke Neuhaus, George P. Rice, Volker Knappertz, Douglas S. Goodin and Gary Cutter and has published in prestigious journals such as PLoS ONE, Brain and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Antonio Scalfari

41 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability

2010 480 citations Antonio Scalfari, Anneke Neuhaus et al. Brain profile →
Smouldering multiple sclerosis: the ‘real MS’

2022 148 citations Gavin Giovannoni, Veronica Popescu et al. profile →
Multiple sclerosis: emerging epidemiological trends and redefining the clinical course

2024 49 citations Emilio Portaccio, Melinda Magyari et al. The Lancet Regional Health - Europe profile →

Peers

Countries citing papers authored by Antonio Scalfari

Since Specialization

Citations

This map shows the geographic impact of Antonio Scalfari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio Scalfari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio Scalfari more than expected).

Fields of papers citing papers by Antonio Scalfari

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonio Scalfari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio Scalfari. The network helps show where Antonio Scalfari may publish in the future.

Co-authorship network of co-authors of Antonio Scalfari

This figure shows the co-authorship network connecting the top 25 collaborators of Antonio Scalfari. A scholar is included among the top collaborators of Antonio Scalfari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonio Scalfari. Antonio Scalfari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study 2025 ·Annals of Neurology ·Paolo A. Muraro, Antonio Zito, Alessio Signori, Maria Pia Sormani, (unknown), (unknown), Roberto Bergamaschi, Alice Mariottini, Omar Malik, (unknown), Victoria Singh‐Curry, Varun Mehra, Majid Kazmi, Ian Gabriel, Eli Silber, Richard Nicholas, Antonio Scalfari	4
2	Early prediction of unfavorable evolution after a first clinical episode suggestive of multiple sclerosis: the EUMUS score 2024 ·Journal of Neurology ·Giulia Mallucci, Ottavia Eleonora Ferraro, María Trojano, Maria Pia Amato, Antonio Scalfari, Mauro Zaffaroni, Elena Colombo, (unknown), Pietro Iaffaldano, Emilio Portaccio, (unknown), Damiano Paolicelli, Lorenzo Razzolini, Cristina Montomoli, Roberto Bergamaschi	0
3	Multiple sclerosis: emerging epidemiological trends and redefining the clinical course breakdown → 2024 ·The Lancet Regional Health - Europe ·Emilio Portaccio, Melinda Magyari, Eva Havrdová, Aurélie Ruet, Bruno Brochet, Antonio Scalfari, Massimiliano Di Filippo, Carmen Tur, Xavier Montalbán, Maria Pia Amato	49
4	Smouldering‐Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions 2024 ·Annals of Neurology ·Antonio Scalfari, Anthony Traboulsee, Jiwon Oh, Laura Airas, Stefan Bittner, Massimiliano Calabrese, José Manuel García‐Domínguez, Cristina Granziera, Benjamin Greenberg, Kerstin Hellwig, Zsolt Illés, Jan Lycke, Veronica Popescu, Francesca Bagnato, Gavin Giovannoni	36
5	Sphingosine‐1‐Phosphate Signalling Inhibition Suppresses Th1‐Like Treg Generation by Reversing Mitochondrial Uncoupling 2024 ·Immunology ·(unknown), Claudia Selck, (unknown), (unknown), (unknown), (unknown), Rafael J. Argüello, Antonio Scalfari, James Varley, Richard Nicholas, Margarita Dominguez‐Villar	0
6	International Consensus on Smoldering Disease in Multiple Sclerosis using the Delphi Method (P11-3.013) 2023 ·Neurology ·Francesca Bagnato, Antonio Scalfari, Jiwon Oh, Laura Airas, Stefan Bittner, Massimiliano Calabrese, José Manuel García‐Domínguez, Cristina Granziera, Benjamin Greenberg, Kerstin Hellwig, Zsolt Illés, Jan Lycke, Anthony Traboulsee, Veronica Popescu, Gavin Giovannoni	1
7	The Sylvia Lawry Centre for Multiple Sclerosis Research (SLCMSR)––Critical review facing the 20 anniversary 2022 ·Multiple Sclerosis and Related Disorders ·Christoph Heesen, Melinda Magyari, Jan‐Patrick Stellmann, Christian Lederer, Gavin Giovannoni, Antonio Scalfari, Martin Däumer	0
8	Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab 2021 ·Journal of Neurology Neurosurgery & Psychiatry ·Steffen Pfeuffer, Tobias Ruck, Refik Pul, Leoni Rolfes, Catharina Korsukewitz, Marc Pawlitzki, Brigitte Wildemann, Luisa Klotz, Christoph Kleinschnitz, Antonio Scalfari, Heinz Wiendl, Sven G. Meuth	20
9	Reported COVID19 symptoms in patients on oral disease modifying treatmentss (DMTS) at a single centre 2020 ·Multiple Sclerosis Journal ·(unknown), (unknown), Arun Dewan, (unknown), (unknown), (unknown), (unknown), Victoria Singh‐Curry, Antonio Scalfari, Omar Malik, Rebecca Nicholas	3
10	The Use of Rituximab in Neurological Diseases; Real World Data from a Neuroscience Centre (2575) 2020 ·Neurology ·(unknown), Paolo A. Muraro, Michael Johnson, (unknown), Jane Pritchard, (unknown), Richard Nicholas, Antonio Scalfari	1
11	The CSF Profile Linked to Cortical Damage Predicts Multiple Sclerosis Activity 2020 ·Annals of Neurology ·Roberta Magliozzi, Antonio Scalfari, (unknown), Stefano Ziccardi, Damiano Marastoni, Francesca B. Pizzini, (unknown), Agnese Tamanti, (unknown), (unknown), Stefania Rossi, (unknown), Marco Castellaro, Stefania Montemezzi, Sarah Rasia, Ruggero Capra, Marco Pitteri, Chiara Romualdi, Richard Reynolds, Massimiliano Calabrese	49
12	Monoclonal Antibody Therapy and Long-term Outcomes in Multiple Sclerosis – The Challenge of Treatment Optimisation 2018 ·European Neurological Review ·Antonio Scalfari, Paolo A. Muraro	1
13	Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis 2017 ·Drugs ·(unknown), Joel Raffel, Antonio Scalfari, Tim Friede, Richard Nicholas	15
14	Regional Distribution and Evolution of Gray Matter Damage in Different Populations of Multiple Sclerosis Patients 2015 ·PLoS ONE ·Massimiliano Calabrese, Richard Reynolds, Roberta Magliozzi, Marco Castellaro, Aldo Morra, Antonio Scalfari, Gabriele Farina, Chiara Romualdi, Alberto Gajofatto, Marco Pitteri, Maria Donata Benedetti, Salvatore Monaco	44
15	Onset of secondary progressive phase and long-term evolution of multiple sclerosis 2013 ·Journal of Neurology Neurosurgery & Psychiatry ·Antonio Scalfari, Ain Neuhaus, Martin Däumer, Paolo A. Muraro, George C. Ebers	201
16	A Web‐based tool for personalized prediction of long‐term disease course in patients with multiple sclerosis 2012 ·European Journal of Neurology ·Ian Galea, Christian Lederer, Ain Neuhaus, Paolo A. Muraro, Antonio Scalfari, Nils Koch‐Henriksen, Christoph Heesen, (unknown), (unknown), Heinz Albrecht, Alexander Winkelmann, Frank Weber, Erik Bahn, M. Häuser, Gilles Edan, George C. Ebers, Martin Däumer	18
17	Early Relapses, Onset of Progression, and Late Outcome in Multiple Sclerosis 2012 ·JAMA Neurology ·Antonio Scalfari, Anneke Neuhaus, Martin Däumer, Gabriele C. DeLuca, Paolo A. Muraro, George C. Ebers	71
18	Age and disability accumulation in multiple sclerosis 2011 ·Neurology ·Antonio Scalfari, Ain Neuhaus, Martin Däumer, George C. Ebers, Paolo A. Muraro	200
19	The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability breakdown → 2010 ·Brain ·Antonio Scalfari, Anneke Neuhaus, Alexandra Degenhardt, George P. Rice, Paolo A. Muraro, Martin Däumer, George C. Ebers	480
20	Clinical prognostic factors in multiple sclerosis: a natural history review 2009 ·Nature Reviews Neurology ·Alexandra Degenhardt, Sreeram V. Ramagopalan, Antonio Scalfari, George C. Ebers	120

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact